Long-term quality of life after radiotherapy for the treatment of anal cancer

Cancer

Volumn 116, Issue 4, 2010, Pages 822-829

  Das, Prajnan ^a   Cantor, Scott B ^a   Parker, Crystal L ^a   Zampieri, Joan B ^a   Baschnagel, Andrew ^a   Eng, Cathy ^a   Delclos, Marc E ^a   Krishnan, Sunil ^a   Janjan, Nora A ^a   Crane, Christopher H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anal cancer; Chemotherapy; Quality of life; Radiotherapy; Sexual dysfunction

Indexed keywords

CAPECITABINE; CISPLATIN; FLUOROURACIL; MITOMYCIN C;

ADULT; ANUS CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION RESPONSE; SCORING SYSTEM; TREATMENT OUTCOME;

ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DEPRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; RADIATION INJURIES; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

EID: 76249118174     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24906     Document Type: Article

References (36)

1. [No authors listed]. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet. 1996;348:1049-1054.
2. Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15:2040-2049.
3. Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996; 14:2527-2539.
4. Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299:1914-1921.
5. Andreyev J. Gastrointestinal symptoms after pelvic radiotherapy: a new understanding to improve management of symptomatic patients. Lancet Oncol. 2007;8:1007-1017.
6. Birgisson H, Pahlman L, Gunnarsson U, et al. Late adverse effects of radiation therapy for rectal cancer-a systematic overview. Acta Oncol. 2007;46:504-516.
7. Johnston MJ, Robertson GM, Frizelle FA. Management of late complications of pelvic radiation in the rectum and anus: a review. Dis Colon Rectum. 2003;46:247-259.
8. Temple LK, Wong WD, Minsky B. The impact of radiation on functional outcomes in patients with rectal cancer and sphincter preservation. Semin Radiat Oncol. 2003;13:469-477.
9. Ashing-Giwa KT, Tejero JS, Kim J, et al. Cervical cancer survivorship in a population based sample. Gynecol Oncol. 2009;112:358-364.
10. Frumovitz M, Sun CC, Schover LR, et al. Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol. 2005;23:7428-7436.
11. Talcott JA, Manola J, Clark JA, et al. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol. 2003;21:3979-3986.
12. Clark JA, Inui TS, Silliman RA, et al. Patients'' perceptions of quality of life after treatment for early prostate cancer. J Clin Oncol. 2003;21:3777-3784.
13. Allal AS, Sprangers MA, Laurencet F, et al. Assessment of long-term quality of life in patients with anal carcinomas treated by radiotherapy with or without chemotherapy. Br J Cancer. 1999;80:1588-1594.
14. Vordermark D, Sailer M, Flentje M, et al. Curative-intent radiation therapy in anal carcinoma: quality of life and sphincter function. Radiother Oncol. 1999;52:239-243.
15. Jephcott CR, Paltiel C, Hay J. Quality of life after non-surgical treatment of anal carcinoma: a case control study of long-term survivors. Clin Oncol (R Coll Radiol). 2004;16: 530-535.
16. Ward WL, Hahn EA, Mo F, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument. Qual Life Res. 1999;8: 181-195.
17. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570-579.
18. Kopec JA, Yothers G, Ganz PA, et al. Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. J Clin Oncol. 2007;25:424-430.
19. Yoo HJ, Kim JC, Eremenco S, et al. Quality of life in colorectal cancer patients with colectomy and the validation of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C), Version 4. J Pain Symptom Manage. 2005;30: 24-32.
20. Sherbourne CD. Social functioning: sexual problems measures. In:Stewart AL, Ware JE, eds. Measuring Functioning and Well-Being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press; 1992: 194-204.
21. Ganz PA, Day R, Ware JE Jr, et al. Base-line quality-of-life assessment in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. J Natl Cancer Inst. 1995;87:1372-1382.
22. Nickel JC, Tripp D, Teal V, et al. Sexual function is a determinant of poor quality of life for women with treatment refractory interstitial cystitis. J Urol. 2007;177:1832-1836.
23. Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002.
24. Das P, Bhatia S, Eng C, et al. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys. 2007;68:794-800.
25. Wilson TR, Alexander DJ, Kind P. Measurement of health-related quality of life in the early follow-up of colon and rectal cancer. Dis Colon Rectum. 2006;49:1692-1702.
26. Ramsey SD, Andersen MR, Etzioni R, et al. Quality of life in survivors of colorectal carcinoma. Cancer. 2000;88:1294-1303.
27. Kuppermann M, Summitt RL Jr, Varner RE, et al. Sexual functioning after total compared with supracervical hysterectomy: a randomized trial. Obstet Gynecol. 2005;105:1309-1318.
28. Chen YJ, Liu A, Tsai PT, et al. Organ sparing by conformal avoidance intensity-modulated radiation therapy for anal cancer: dosimetric evaluation of coverage of pelvis and inguinal/femoral nodes. Int J Radiat Oncol Biol Phys. 2005;63:274-281.
29. Menkarios C, Azria D, Laliberte B, et al. Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans. Radiat Oncol. 2007;2:41.
30. Kachnic L, Tsai HK, Willins J, et al. Dose-painted intensity modulated radiation therapy for anal cancer: dosimetric comparison and acute toxicity [abstract]. Int J Radiat Oncol Biol Phys. 2006;66:S280. Abstract 2126.
31. Milano MT, Jani AB, Farrey KJ, et al. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys. 2005;63:354-361.
32. Salama JK, Mell LK, Schomas DA, et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol. 2007;25:4581-4586.
33. Andreyev HJ. Gastrointestinal problems after pelvic radiotherapy: the past, the present and the future. Clin Oncol (R Coll Radiol). 2007;19:790-799.
34. Peltier A, van Velthoven R, Roumeguere T. Current management of erectile dysfunction after cancer treatment. Curr Opin Oncol. 2009;21:303-309.
35. Krychman ML, Pereira L, Carter J, et al. Sexual oncology: sexual health issues in women with cancer. Oncology. 2006; 71:18-25.
36. Tournier-Rangeard L, Mercier M, Peiffert D, et al. Radio-chemotherapy of locally advanced anal canal carcinoma: prospective assessment of early impact on the quality of life (randomized trial ACCORD 03). Radiother Oncol. 2008; 87:391-397.